Physician profile
Michael D Vanpelt
NPI 1174749915
$10,423.37
in general payments reported to CMS, 2019-2025
30 companies · $4,037 in 2025
The $4,037 reported for 2025 was more than what 92% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,719 · 2020: $273 · 2021: $2,158 · 2022: $552 · 2023: $493 · 2024: $1,192 · 2025: $4,037.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,439 · Travel and Lodging: $1,283 · Consulting Fee: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,438.50 |
| Travel and Lodging | $1,283.17 |
| Consulting Fee | $1,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pylant Medical | $2,661.90 | 2019-2025 | |
| Synthes Gmbh | $2,425.53 | 2025 | |
| Stryker Corporation | $1,958.78 | 2019-2025 | Infinity Adaptis, Augment Injectable, Axs Infinity Ls |
| Depuy Synthes Sales INC. | $518.14 | 2019-2025 | Hammerlock, Motoband, Monovisc |
| Kerecis Limited | $327.09 | 2019-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Treace Medical Concepts, INC. | $297.32 | 2023-2025 | |
| Smith+Nephew, INC. | $279.03 | 2019-2025 | Evos, Salto Talaris Total Ankle Prosthesis, Pico 14 |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $227.49 | 2019-2022 | |
| Integra Lifesciences Corporation | $174.09 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Osteoremedies, LLC | $152.61 | 2025 | Xperience, Blastx |
| Bone Support INC. | $149.66 | 2024 | Ceramentbone Void Filler, Cerament G |
| Ferring Pharmaceuticals INC. | $135.02 | 2019-2025 | Euflexxa |
| Vertex Pharmaceuticals Incorporated | $124.92 | 2025 | |
| Orthofix Medical, INC. | $123.48 | 2022 | |
| Melinta Therapeutics, LLC | $115.98 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $109.06 | 2019-2020 | |
| Next Science LLC | $104.86 | 2024-2025 | Xperience, Blastx |
| Zimmer Biomet Holdings, INC. | $94.19 | 2019-2020 | |
| Nuvasive Specialized Orthopedics, INC. | $90.66 | 2023 | Precice Intramedullary Limb Lengthening System |
| Trilliant Surgical LLC. | $80.81 | 2019 | |
| Musculoskeletal Transplant Foundation INC. | $75.80 | 2024 | |
| Averitas Pharma INC. | $45.03 | 2024 | Qutenza |
| Bioventus LLC | $34.58 | 2022 | |
| Davol INC. | $31.41 | 2020 | |
| Siemens Medical Solutions USA, INC. | $19.13 | 2023 | Multitom Rax |
| Sanofi-Aventis U.S. LLC | $16.12 | 2023 | |
| Nvision Biomedical Technologies, INC. | $13.34 | 2022 | |
| Tenex Health INC. | $13.20 | 2019 | |
| Pacira Therapeutics, INC. | $12.45 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Vanpelt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.